How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,355 results for

aspirin and gastrointestinal bleeding

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Diagnosis and Management of Small Bowel Bleeding

Diagnosis and Management of Small Bowel Bleeding nature publishing group 1265 © 2015 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY PRACTICE GUIDELINES Bleeding from the small intestine remains a relatively uncom- mon event, accounting for ~5–10% of all patients presenting with gastrointestinal (GI) bleeding ( 1,2 ). Known previously as obscure GI hemorrhage (OGIB), we propose in this guideline that the former term referred to as OGIB be reclassifi ed (...) ,” “Meckel’s diverticulum,” ACG Clinical Guideline: Diagnosis and Management of Small Bowel Bleeding L a ur en B . G er s o n , MD , MS c, F A C G 1 , J eff L. Fidler , MD 2 , D a v id R . C a v e , MD , P hD , F A C G 3 a n d J o n a t h a n A. L eig h t o n , MD , F A C G 4 Bleeding from the small intestine remains a relatively uncommon event, accounting for ~5–10% of all patients presenting with gastrointestinal (GI) bleeding. Given advances in small bowel imaging with video capsule endoscopy (VCE

2015 American College of Gastroenterology

122. Perioperative Aspirin Response in Patients Undergoing Vascular Surgery

Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: • Vascular patients requiring treatment for peripheral artery disease (PAD) and/or carotid stenosis are included in the study. Exclusion Criteria: non-adherence to the antiplatelet medication abnormal platelet count in patients, current gastrointestinal disorders, current infections, serious concomitant medical conditions (such as recent gastrointestinal bleeding, cancer, severe cardiac or liver disorders) known (...) Perioperative Aspirin Response in Patients Undergoing Vascular Surgery Perioperative Aspirin Response in Patients Undergoing Vascular Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Perioperative

2018 Clinical Trials

123. Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum

that low-dose Aspirin prevents diseases of heart and blood vessels as well as cancer of the colon and rectum and it is also associated with risk of bleeding. In this study, they want to learn how patients regard the benefits and risks of low-dose Aspirin for the prevention of these diseases. The researchers also want to learn how patients balance these risks and benefits. Condition or disease Intervention/treatment Cardiovascular Disease, Colorectal Cancer Drug: Acetylsalicylic acid (Aspirin, BAYE4465 (...) Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Aspirin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme

2018 Clinical Trials

124. Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

History of confirmed allergy to dabigatran etexilate Active cerebral bleeding, or active non-cerebral bleeding requiring blood transfusions (any absolute contra-indications to anti-coagulation). History of intraocular, spinal, retroperitoneal or a traumatic intra-articular bleeding unless the causative factor has been permanently eliminated or repaired (e.g. by surgery) Gastrointestinal (GI) haemorrhage within one month prior to screening, unless, in the opinion of the Investigator, the cause has been (...) Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study). Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study). - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2018 Clinical Trials

125. Influence of Aspirin on Human Gut Microbiota Composition and Metabolome

for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: NSAID naïve during the last month; absence of drugs, nutrient supplements, probiotics, prebiotics and synbiotics that might interfere with microbial homeostasis for all participants; no past history of gastrointestinal bleeding or ulcers; absence of historical aspirin-induced side effects; voluntary and willing to cooperate during treatment; and consent (...) Influence of Aspirin on Human Gut Microbiota Composition and Metabolome Influence of Aspirin on Human Gut Microbiota Composition and Metabolome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Influence

2018 Clinical Trials

126. ASPIRIN Trial Belgium

table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Ethisch Comité, UZA, University Hospital, Antwerp: Colonic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Colonic Diseases Aspirin Recurrence Digestive System Diseases Intestinal Diseases Disease Attributes Pathologic Processes Additional relevant MeSH terms: Layout (...) table for MeSH terms Colonic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Aspirin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin

2018 Clinical Trials

127. Timed Aspirin Chronobiome

or their components. Subjects who are sensitive or allergic to aspirin or other NSAIDs. Subjects with documented history of any gastrointestinal disorders, including bleeding ulcers. History of significant cardiovascular disease (including stroke or TIA), renal, hepatic, respiratory (except infections which longer > 6 months prior to screening), immune, endocrine, hematopoietic disorder or neurological disorders. History of cancer within the last 5 years (except for cutaneous basal cell or squamous cell cancer (...) and willing to provide written informed consent prior to any study procedures being performed. Exclusion Criteria: Female subjects who are pregnant or nursing a child. Subjects who have received an investigational drug or used an experimental medical device within 30 days prior to screening, or who gave a blood donation of ≥ one pint within 8 weeks prior to screening. Subjects with any coagulation, bleeding or blood disorders. Subjects who are sensitive or allergic to celecoxib (Celebrex) or aspirin

2018 Clinical Trials

128. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). Full Text available with Trip Pro

of the increased risk of intracranial hemorrhage, severe extracranial hemorrhage requiring hospitalization or transfusion, and gastrointestinal bleeding in old patients receiving aspirin therapy.The study is registered at ClinicalTrials.gov [NCT00225849]. (...) 22/250; HR 0.44 [95% CI 0.20-0.93]; P = 0.03). This subgroup was also found to contain significant larger proportions of patients with elevated body mass index, patients with diabetes mellitus, and smokers (P < 0.001). Old patients also showed differences in bleeding outcomes. Serious extracranial hemorrhage requiring transfusion or hospitalization occurred significantly more frequently in the aspirin-treated group than in the non-aspirin-treated group (35 [0.88%] vs 18 [0.45%]; HR 1.96 [1.11

2018 American journal of cardiovascular drugs : drugs, devices, and other interventions Controlled trial quality: predicted high

129. Utilization of Aspirin and Statin in Management of Coronary Artery Disease in Patients with Cirrhosis Undergoing Liver Transplant Evaluation. Full Text available with Trip Pro

was performed as part of the LT evaluation in all patients over the age of 50 years or with CAD risk factors, even if they were younger than 50. Optimal CAD medical management was defined as the use of both statin and aspirin, unless a contraindication was documented. Impact of these medications on hepatic decompensation, renal function, gastrointestinal bleeding, and need for transfusion was evaluated. CAD was detected in 84/228 (36.8%) patients. Lipid profile was similar in patients with and without CAD (...) of aspirin therapy was not associated with increased risk acute variceal hemorrhage, gastrointestinal bleeding, or worsening anemia. In conclusion, in decompensated cirrhosis, lipid profile alone is unable to risk stratify patients with CAD. Statin and aspirin appear to be safe. However, they are significantly underutilized for the management of CAD in this patient population. Liver Transplantation 24 872-880 2018 AASLD.© 2018 by the American Association for the Study of Liver Diseases.

2018 Liver Transplantation

130. Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. (Abstract)

retrospectively identified 5666 patients who received aspirin twice daily for 4 to 6 weeks after TKA. A total of 1327 patients received 81-mg BID and 4339 patients received 325-mg BID aspirin. Postoperative complications collected were VTEs (DVT and PE), bleeding (gastrointestinal or wound bleeding), and mortality.The incidence of VTE was 1.5% in the 325-mg group and 0.7% in the 81-mg group (P = .02). Symptomatic DVT was 1.4% in the 325-mg aspirin compared with 0.3% for the 81-mg aspirin (P = .0009 (...) Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA). The optimal prophylactic aspirin dose has not been established. The study aims to compare 2 aspirin regimens with regard to the incidence of (1) symptomatic deep venous thrombosis (DVT), (2) pulmonary embolism (PE), (3) bleeding, and (4) mortality within 90 days after TKA.We

2018 Journal of Arthroplasty

131. Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis. Full Text available with Trip Pro

Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis. Proton pump inhibitors (PPIs) are usually prescribed to protect against gastrointestinal bleeding in patients on dual antiplatelet therapy. This meta-analysis reviewed clinical outcomes in patients taking aspirin and clopidogrel, with and without concomitant PPIs to address concerns of adverse reactions.We searched PubMed, Embase, and the Cochrane (...) Library for articles published between January 1, 2010 and April 11, 2017. The primary end points were major adverse cardiovascular events and gastrointestinal bleeding. Secondary end points were myocardial infarction, stent thrombosis, revascularization, cardiogenic death, and all-cause mortality.The meta-analysis included 33,492 patients in 4 randomized controlled trials and 8 controlled observational studies. Overall, patients taking PPIs had statistical differences in major adverse cardiovascular

2018 Medicine

132. Aspirin in primary prevention for patients with diabetes: still a matter of debate. Full Text available with Trip Pro

to evaluate the occurrence of any CV event in a cohort of patients with diabetes and concluded that low-dose aspirin did not influence the risk for CV events while increasing the risk for gastrointestinal (GI) bleeding. Reasons for this result can be found in the role of diabetic platelets, which are known to be hyperreactive, thus producing intensified adhesion, activation, and aggregation. In this setting, other associated metabolic conditions can concur to enhance platelet adhesion and activation (...) Aspirin in primary prevention for patients with diabetes: still a matter of debate. Patients with diabetes are at high cardiovascular (CV) risk due to an exaggerated platelet activation and aggregation. In the first 2000s low-dose aspirin was first recommended for primary prevention, but then re-discussed.This short narrative review, based on the material searched for and obtained via PubMed up to February 2018, aims at clarifying this controversial topic.The JPAD2 study has been designed

2018 European journal of clinical investigation

133. Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI. Full Text available with Trip Pro

and control group by the draw, with 43 patients in each group. All patients were routinely treated with dual antiplatelet therapy with aspirin plus ticagrelor. Omeprazole was used in the observation group and placebo was used in the control group. Baseline data of patients, platelet response index (PRI) ADP-induced platelet aggregation (ADP-Ag), major adverse cardiac events (MACE), and incidence of bleeding events were recorded and compared.PRI and ADP-Ag at 7 days, 1 month, and 6 months after operation (...) patients undergoing primary PCI, omeprazole can reduce the incidence of gastrointestinal bleeding without reducing the antiplatelet aggregation effect of ticagrelor or increasing the risk of MACE, which is worthy of clinical promotion.Copyright © 2019 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.

2019 Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese Controlled trial quality: uncertain

134. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Full Text available with Trip Pro

Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lifelong antiplatelet treatment is recommended after ischaemic vascular events, on the basis of trials done mainly in patients younger than 75 years. Upper gastrointestinal bleeding is a serious complication, but had low case fatality in trials of aspirin and is not generally thought to cause long-term disability. Consequently, although (...) co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointestinal bleeds by 70-90%, uptake is low and guidelines are conflicting. We aimed to assess the risk, time course, and outcomes of bleeding on antiplatelet treatment for secondary prevention in patients of all ages.We did a prospective population-based cohort study in patients with a first transient ischaemic attack, ischaemic stroke, or myocardial infarction treated with antiplatelet drugs (mainly aspirin based, without

2017 Lancet

135. Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes nature publishing group 223 © 2015 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY PRACTICE GUIDELINES H e r e di t a r y gastr o in t e stinal (GI) ca ncer syndr o mes r e p r es en t a phenotypically diverse group of disorders that exhibit distinct patterns of inheritance in an individual’s progeny. Over the past few decades, the expansion of familial cancer registries and ad (...) by a summary of the supporting evidence ( Tables 1 and 2 ). A ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes Sa p n a S y n ga l , MD , MP H, F A C G 1 , 2 , 3 , R a n d a l l E. B ra n d , MD , F A C G 4 , J a m es M. C h ur c h , MD , F A C G 5 , 6 , 7 , F ra n cis M. G i a r diello , MD 8 , H e a t her L. H a m p el , MS, C GC 9 a n d R a n d a l l W . B ur t , MD , F A C G 10 This guideline presents recommendations for the management of patients

2015 American College of Gastroenterology

136. Misoprostol for Small Bowel Ulcers and Obscure Bleeding Due to Aspirin or Nonsteroidal Antiinflammatory Drugs

of potentially bleeding lesions on full upper endoscopy and colonoscopy. Taking low-dose aspirin (75-325m/ day) and/ or NSAIDs MAIN EXCLUSION CRITERIA: Incomplete upper endoscopy or colonoscopy Systemic disease that is unstable at the time of randomisation (unstable vital signs; ongoing non-gastrointestinal investigations; frequent modifications to treatment) Intake of certain drugs: high-dose steroids (>7.5-mg prednisolone/ day), cytotoxic drugs, or warfarin. Upper gastrointestinal lesions: oesophageal (...) Misoprostol for Small Bowel Ulcers and Obscure Bleeding Due to Aspirin or Nonsteroidal Antiinflammatory Drugs Misoprostol for Small Bowel Ulcers and Obscure Bleeding Due to Aspirin or Nonsteroidal Antiinflammatory Drugs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2014 Clinical Trials

137. Gastrointestinal Complications Warranting Invasive Interventions Following Total Joint Arthroplasty. (Abstract)

institution between January 2012 and May 2018 who had GI complications requiring an invasive procedure within 30 days of TJA were identified and retrospectively chart reviewed. Descriptive statistics were used to evaluate these patients.Of 19,090 TJAs in a 6-year period, 34 patients (0.18%) required invasive procedures for GI complications within 30 days of the index surgery. Twenty-two (64%) of the required procedures were endoscopy for suspected GI bleeding. Within this cohort, aspirin was the most (...) Gastrointestinal Complications Warranting Invasive Interventions Following Total Joint Arthroplasty. Gastrointestinal (GI) complications following total joint arthroplasty (TJA) are uncommon but can be associated with substantial morbidity and mortality. The current literature on GI complications that warrant invasive procedures after TJA is lacking. This study reviews the incidence and outcomes of GI complications after TJA that went on to require invasive procedures.All TJA patients at our

2019 Journal of Arthroplasty

138. [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease]

), respectively. The attributable risk of aspirin use for CVDs was 17.5%. The risk of cardiovascular thrombotic events, including myocardial infarction, ischemic stroke, and transient ischemic accident, had also increased by 34% (95% CI, 1.18-1.52). Besides, the hazard ratio for gastrointestinal bleeding, which is a well-known adverse reaction of aspirin significantly increased (HR=1.14; 95% CI, 1.09-1.19). In this study of diabetic patients, low aspirin use did not decrease the risk of CVD events, although (...) it did control for potential confounding. The possible interaction between DM and mechanism of aspirin resulted in reduced anti-thrombotic effect and increased CVD risk for DM patients. In addition, low dose aspirin use was associated with increased risk of bleeding events. Further studies are needed to confirm these findings to assess long term follow-up data and to collect unmeasured confounding factors. It may provide evidence for revising clinical guidelines that recommend cautious usage of low

2012 Health Technology Assessment (HTA) Database.

139. Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer

for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Idiopathic gastroduodenal ulcer bleeding is defined as described in our previous studies [12-15]: Gastroduodenal ulcer bleeding is diagnosed based on: i. History of symptoms of upper gastrointestinal bleeding with endoscopically proven gastroduodenal ulcers; Idiopathic ulcer is diagnosed based on: i. No experience of ulcerogenic agents (e.g. aspirin, NSAIDs (...) 18, 2018 Last Update Posted : September 19, 2018 See Sponsor: Chinese University of Hong Kong Information provided by (Responsible Party): Prof Wong, Lai Hung Grace, Chinese University of Hong Kong Study Details Study Description Go to Brief Summary: Patients with a history of idiopathic gastroduodenal ulcer bleeding face an increased risk of recurrent ulcer gastrointestinal bleeding. Our ongoing clinical trial demonstrates a possible reduced risk of recurrent idiopathic gastroduodenal ulcer

2018 Clinical Trials

140. SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance to Examine the Safety of Cessation of Dual Anti-Platelet Therapy in High Bleeding Risk Patients at One Month

if performed > 7 days following the index procedure or if SYNERGY stents are not used) Subject has a known allergy to: contrast (that cannot be adequately pre-medicated), the SYNERGY Stent®s system or protocol-required concomitant medications (e.g., everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors and aspirin) Subject previously treated at any time with intravascular brachytherapy Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding (...) Model Description: DAPT or Dual Antiplatelet Therapy is a combination of two medications given after a percutaneous coronary intervention (PCI) with a drug eluting stent. The medications used for DAPT are low dose Aspirin (81mg) and one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient). Because the patients are considered to be at a high risk for bleeding due to one or a combination of reasons this study is trying to determine if a shorter use

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>